Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAC vs TC in Neoadjuvant Triple-Negative or Her2 Positive Breast Cancer
NCT00912444Phase 3Terminated
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jul 2009
- Primary completion
- May 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of docetaxel, cyclophosphamide, doxorubicin, epirubicin in triple negative breast cancer (TNBC), HER2-positive breast cancer, sponsored by Shanghai Jiao Tong University School of Medicine. Started Jul 2009; status: terminated.
02
Drugs
docetaxelcyclophosphamidedoxorubicinepirubicin
03
Conditions
triple negative breast cancer (TNBC)HER2-positive breast cancer
Beyond the preview
Go deeper on NCT00912444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00912444.